Navigation Links
FDA Grants Permanent Hair Reduction Labeling for TRIA Laser Hair Removal System

DUBLIN, Calif., Jan. 11 /PRNewswire/ -- TRIA Beauty, the leader in light-based therapeutic beauty devices, today announced it received an additional over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for its flagship product, TRIA Laser Hair Removal System (LHRS). The TRIA laser is now FDA-cleared for permanent hair reduction, making it the first and only at-home hair removal device clinically proven to deliver permanent results.

"Our new FDA-clearance validates the superiority of TRIA laser over other at-home hair removal systems," said Kevin Appelbaum, CEO of TRIA Beauty. "This announcement is a testament to the advanced engineering and patented design intelligence that is the essence of TRIA Beauty."

According to a recent Dermatology Times survey, 82% of dermatologists prefer lasers to any other technology to achieve permanent hair removal. TRIA LHRS is the only at-home hair removal device on the market that utilizes a diode laser, the same technology used in professional laser hair removal systems and still considered the gold-standard treatment. In fact, the TRIA LHRS was developed by the scientists who invented the professional technology more than a decade ago.

The TRIA LHRS first received FDA clearance in February 2008 and has been recognized by industry authorities like Allure, WWD Beauty Biz, and Advertising Age for its game-changing innovation. In late 2009, TRIA Beauty launched a second generation TRIA LHRS that provides more power settings for improved comfort and performance. The second generation TRIA laser is sold at a 40% lower price than the original, making permanent hair reduction even more affordable to consumers.

This additional OTC clearance for TRIA LHRS comes just a day after TRIA Beauty received OTC clearance from the FDA for a proprietary hand-held blue light device designed for at-home use for the treatment of mild to moderate inflammatory acne. The new TRIA blue-light device is 10 times more powerful than other at-home blue light devices, continuing TRIA Beauty's heritage of innovation in beauty. It will be part of a dermatologist-validated system that will launch in Spring 2010.

The TRIA LHRS is priced at $595 and is available at as well as on QVC, and at Bloomingdales, Neiman Marcus, Nordstrom, Bergdorf Goodman, STUDIO at Fred Segal, Bliss Spas and select physician offices.

About TRIA Beauty

TRIA Beauty, formerly known as SpectraGenics, brings home the very best in light-based skincare products. In 2008, TRIA Beauty revolutionized the hair removal industry with the first and only FDA-cleared laser hair removal system available for at home use, the TRIA Laser Hair Removal System. In 2010 TRIA Beauty will launch a clear skin system featuring FDA-cleared blue light technology that offers the most effective therapeutic dose of blue light for at-home use. FDA-cleared, clinically proven and easy to use, TRIA Beauty is committed to real science with beautiful results.




Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Labor Department Awards $10.1 Million for Safety and Health Training Grants
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide
4. USAID Announces First Malaria Communities Program Grants
5. The Highmark Foundation Awards $580,000 in Highmark Healthy High 5 Grants to Four Non-Profit Organizations
6. KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants
7. FDA Grants Clearance to Langford IC Systems, Inc.
8. Dienst Custom Homes Grants Over 40 Wishes in Three Years
9. United Animal Nations Offers Financial Assistance Grants of up to $500 to Help Southern California Fire Victims Obtain Vet Care, Temporary Boarding for Pets
10. PA Health Department Awards Community Primary Care Challenge Grants
11. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, ... a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program ... as a finalist in the category of Digital Solutions for its innovative, industry-leading ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015  Eyeon Therapeutics has ... dry eye treatments based on a charged hydrophilic ... delivery CDMO.  The product has been shown to ... previously published.  Mark Mitchnick , MD, CEO ... protection to additional polymers in conjunction with a ...
(Date:12/1/2015)... , December 1, 2015 --> ... report "Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, ... Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020", ... to reach USD 73,529.2 Million by 2020 from USD 40,281.6 ... to 2020. Browse 37 ...
(Date:12/1/2015)... HERTFORDSHIRE, England , BANGALORE, India ... 2015  Mylan N.V. (NASDAQ, TASE: MYL) today announced ... upon regulatory approval and for developing country markets funded ... + Lamivudine 300 mg + Efavirenz 400 mg) for ... Clinton Health Access Initiative (CHAI) to develop TLE400. The ...
Breaking Medicine Technology: